###begin article-title 0
###xml 74 79 <span type="species:ncbi:10090">Mouse</span>
###xml 84 89 <span type="species:ncbi:9606">Human</span>
Differential Roles of the PKC Novel Isoforms, PKCdelta and PKCepsilon, in Mouse and Human Platelets
###end article-title 0
###begin p 1
Conceived and designed the experiments: CP KT ACP SW. Performed the experiments: KT JMA CEH BG MBP ACP. Analyzed the data: KT. Wrote the paper: CP KT ACP SW.
###end p 1
###begin p 2
Current address: The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom
###end p 2
###begin p 3
Current address: Cell Signalling and Biochemistry Lab, Discovery Biology, Novartis Institutes for Biomedical Research, Horsham, United Kingdom
###end p 3
###begin title 4
Background
###end title 4
###begin p 5
Increasing evidence suggests that individual isoforms of protein kinase C (PKC) play distinct roles in regulating platelet activation.
###end p 5
###begin title 6
Methodology/Principal Findings
###end title 6
###begin p 7
###xml 96 101 <span type="species:ncbi:10090">mouse</span>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 157 162 <span type="species:ncbi:9606">human</span>
###xml 364 369 <span type="species:ncbi:10090">mouse</span>
###xml 537 542 <span type="species:ncbi:10090">mouse</span>
###xml 551 556 <span type="species:ncbi:9606">human</span>
###xml 682 687 <span type="species:ncbi:10090">mouse</span>
###xml 956 961 <span type="species:ncbi:10090">mouse</span>
In this study, we focus on the role of two novel PKC isoforms, PKCdelta and PKCepsilon, in both mouse and human platelets. PKCdelta is robustly expressed in human platelets and undergoes transient tyrosine phosphorylation upon stimulation by thrombin or the collagen receptor, GPVI, which becomes sustained in the presence of the pan-PKC inhibitor, Ro 31-8220. In mouse platelets, however, PKCdelta undergoes sustained tyrosine phosphorylation upon activation. In contrast the related isoform, PKCepsilon, is expressed at high levels in mouse but not human platelets. There is a marked inhibition in aggregation and dense granule secretion to low concentrations of GPVI agonists in mouse platelets lacking PKCepsilon in contrast to a minor inhibition in response to G protein-coupled receptor agonists. This reduction is mediated by inhibition of tyrosine phosphorylation of the FcRgamma-chain and downstream proteins, an effect also observed in wild-type mouse platelets in the presence of a PKC inhibitor.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
These results demonstrate a reciprocal relationship in levels of the novel PKC isoforms delta and epsilon in human and mouse platelets and a selective role for PKCepsilon in signalling through GPVI.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 551 554 544 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Watson1">[1]</xref>
###xml 697 698 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 740 742 726 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 818 821 804 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Nishizuka1">[2]</xref>
###xml 971 974 957 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Watson2">[3]</xref>
###xml 976 979 962 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Atkinson1">[4]</xref>
###xml 1108 1111 1094 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-PolanowskaGrabowska1">[5]</xref>
###xml 1113 1116 1099 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Wentworth1">[6]</xref>
###xml 1118 1121 1104 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-vanWilligen1">[7]</xref>
###xml 1123 1126 1109 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Abrams1">[8]</xref>
The major receptors which induce platelet activation signal by different mechanisms although many converge on the activation of the protein kinase C (PKC) family of serine/threonine kinases. For example, thrombin signals through heterotrimeric Gq proteins leading to activation of phospholipase C (PLC)beta isoforms, while the collagen receptor GPVI activates a distinct isoform, PLCgamma2, through an immunoreceptor tyrosine-based activation motif (ITAM)-dependent pathway, involving sequential activation of Src, Syk and Tec family tyrosine kinases [1]. PLCbeta and gamma isoforms hydrolyse phosphatidylinositol 4,5-bisphosphate to generate the second messengers inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol which mobilise Ca2+ from intracellular stores and activate classical and novel isoforms of PKC [2]. PKCs play a critical role in platelet activation as pharmacological inhibitors of PKC inhibit aggregation and secretion by the majority of agonists [3], [4]. Many PKC substrates have been identified in platelets including components of the secretory machinery and signalling molecules [5], [6], [7], [8].
###end p 11
###begin p 12
###xml 143 146 143 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Mellor1">[9]</xref>
###xml 259 261 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 354 356 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 472 474 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 858 862 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Moussazadeh1">[10]</xref>
###xml 864 868 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Crosby1">[11]</xref>
###xml 870 874 821 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Hall1">[12]</xref>
###xml 876 880 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Murugappan1">[13]</xref>
###xml 1252 1256 1188 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Crosby2">[14]</xref>
###xml 1258 1262 1194 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Soriani1">[15]</xref>
###xml 1376 1380 1306 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Crosby1">[11]</xref>
###xml 1459 1463 1389 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Buensuceso1">[16]</xref>
###xml 659 664 <span type="species:ncbi:9606">human</span>
###xml 1100 1105 <span type="species:ncbi:9606">human</span>
###xml 1360 1365 <span type="species:ncbi:9606">human</span>
###xml 1443 1448 <span type="species:ncbi:9606">human</span>
PKC consists of nine structurally related isoforms, sub-divided into three groups based on mechanism of activation and structural similarities [9]. The classical PKC isoforms (alpha, beta, gamma), contain domains conferring regulation to diacylglycerol and Ca2+ and require both for full activation. The novel isoforms (delta, epsilon, theta, eta) are Ca2+-independent whereas the atypical isoforms iota  /lambda and zeta are not directly regulated by diacylglycerol or Ca2+. Initial evidence for the involvement of the novel PKC isoforms in platelet activation came from studies monitoring tyrosine phosphorylation of these proteins following stimulation of human platelets. PKCdelta is tyrosine phosphorylated at two distinct sites, Tyr311 and 565, in response to activation of GPVI and PAR receptors, but not by the major platelet integrin, alphaIIbbeta3 [10], [11], [12], [13]. This provides a potential mechanism for both direct regulation of PKCdelta activity and in initiating downstream signalling through recruitment of SH2 domain containing proteins. PKCtheta is tyrosine phosphorylated in human platelets in response to collagen, the snake toxin Alboaggregin A (which interacts with both GPVI and GP-Ib-IX-V) and downstream of alphaIIbbeta3 [14], [15]. PKCepsilon has also been reported to be tyrosine phosphorylated downstream of Alboaggregin A in human platelets [11], although others have been unable to detect its expression in human platelets [16].
###end p 12
###begin p 13
###xml 161 169 161 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Crosby1">[11]</xref>
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Murugappan2">[17]</xref>
###xml 373 377 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Soltoff1">[18]</xref>
###xml 379 383 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Davies1">[19]</xref>
###xml 758 762 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Soriani1">[15]</xref>
###xml 764 768 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Buensuceso1">[16]</xref>
###xml 923 927 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Pula1">[20]</xref>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 783 788 <span type="species:ncbi:10090">mouse</span>
Further evidence for different functions of individual PKC isoforms downstream of different receptors relied on inhibitors with preferential isoform specificity in vitro[11], [17]. However the selectivity of these inhibitors within a cell remains unclear and many have been shown to have additional effects, including the so-called selective PKCdelta inhibitor, rottlerlin [18], [19]. More recently, studies of platelets derived from mice lacking individual PKC isoforms have proven invaluable in providing information about specific roles of individual isoforms. Platelets deficient in PKCbeta or PKCtheta both show a deficiency in spreading on immobilised fibrinogen, consistent with a role for these isoforms in mediating signals induced by alphaIIbbeta3 [15], [16]. In contrast, mouse platelets lacking PKCdelta show enhanced aggregation and spreading when stimulated by collagen, suggesting a feedback inhibitory role [20].
###end p 13
###begin p 14
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 220 225 <span type="species:ncbi:9606">human</span>
###xml 230 235 <span type="species:ncbi:10090">mouse</span>
The present study focuses on two novel isoforms, PKCdelta and PKCepsilon, in mouse and human platelets. Unexpectedly, we observed a reciprocal relationship in expression, with PKCdelta detected at high and low levels in human and mouse platelets, respectively, and vice versa for PKCepsilon. We reveal a novel role for PKCepsilon in aggregation to collagen, but not to G protein-coupled receptor agonists, mediated through tyrosine phosphorylation of FcRgamma-chain.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Reagents
###end title 16
###begin p 17
###xml 545 549 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Castrillo1">[21]</xref>
###xml 982 986 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Jarvis1">[22]</xref>
###xml 988 992 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Gries1">[23]</xref>
###xml 1070 1074 1044 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Poole1">[24]</xref>
###xml 1076 1080 1050 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Auger1">[25]</xref>
###xml 1082 1086 1056 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Best1">[26]</xref>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 795 801 <span type="species:ncbi:9796">equine</span>
###xml 916 922 <span type="species:ncbi:9796">equine</span>
Anti-PKCepsilon (clone 21) and theta antibodies were purchased from BD Pharmingen (Oxford, UK) and anti-PKCeta from Santa Cruz Biotechnology, Inc. (CA, USA). Anti-PKCdelta antibodies were from BD Pharmingen (Oxford, UK) (clone 14) and Santa Cruz Biotechnology, Inc. (CA, USA) (sc-937) used for western blotting and immunoprecipitation, respectively. Polyclonal antibodies to PLCgamma2 (DN84), Syk (BR15) and Btk (BL7) were kindly provided by Dr Mike Tomlinson (formerly of DNAX Research Institute, Palo Alto, CA, USA). PKCepsilon-deficient mice [21] were bred as heterozygotes on a B6 background and all results compared to wild type litter-matched controls. P-PACK (D-Phe-Pro-Arg-chloromethylketone, HCl) and AEBSF were from Merck Biosciences Ltd (Nottingham, UK). Fibrillar horm collagen from equine tendon was purchased from Nycomed (Linz, Austria). Horm collagen is a preparation of native collagen fibrils from equine tendon which mainly contains predominantly type I collagen [22], [23]. Other reagents were from Sigma (Poole, UK), or previously described sources [24], [25], [26].
###end p 17
###begin title 18
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 10 15 <span type="species:ncbi:10090">mouse</span>
Human and mouse platelet preparation
###end title 18
###begin p 19
###xml 292 296 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Auger1">[25]</xref>
###xml 369 370 365 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 373 374 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 399 400 395 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 441 442 437 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 609 610 605 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 797 801 785 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Auger1">[25]</xref>
###xml 905 906 893 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
Studies on human platelets were carried out with ethical approval from the Central Oxford Research Committee (Ref: C00:203), with written informed consent obtained from all donors. Washed platelets were prepared from platelet rich plasma (PRP) in the presence of prostacyclin (0.1 microg/ml) [25]. Blood was resuspended in Tyrode's-Hepes buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM Hepes, 5 mM glucose and 1 mM MgCl2, pH7.3). Animals were bred and blood removed under an approved Home Office Licence. Blood was drawn either by cardiac puncture or from the vena cavae of terminally CO2-narcosed mice, originally anaesthetised with gaseous isofluorane. Blood was taken into 100 microl ACD and 200 microl modified Tyrode's-Hepes buffer. Platelets were prepared as described [25], except final separation from PRP was by spinning at 1,000 g for 6 min. They were resuspended at 2-5x108/ml in Tyrode's-Hepes.
###end p 19
###begin title 20
Platelet aggregation and spreading
###end title 20
###begin p 21
###xml 147 148 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 308 312 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Thornber1">[27]</xref>
###xml 491 492 477 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Aggregation was performed at 37degreesC with constant stirring (1200 rpm) in a Chronolog 490-2D aggregometer (Labmedics, Manchester, UK) using 2x108/ml platelets in a sample size of 300 microl. Secretion of ATP was measured using luciferase-luciferin reagent. Platelet spreading was carried out as described [27]. Where indicated, apyrase (2.5 units/ml) and indomethacin (10 microM) were added 60 sec before experimentation to prevent the action of released ADP or formation of thromboxane A2, respectively.
###end p 21
###begin title 22
Flow Cytometry
###end title 22
###begin p 23
###xml 76 80 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Best1">[26]</xref>
Expression of the cell surface glycoproteins was measured by flow cytometry [26].
###end p 23
###begin title 24
Immunoprecipitation and western blotting
###end title 24
###begin p 25
###xml 33 34 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 236 240 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Marshall1">[28]</xref>
###xml 661 665 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Auger1">[25]</xref>
300 microl washed platelets (5x108/ml) were stimulated under stirring conditions (1200 rpm), terminated by addition of an equal volume of ice-cold 2% NP-40 lysis buffer and immunoprecipitations (IPs) carried out as previously described [28]. For PKCdelta, IPs were carried out using monoclonal antibody against PKCdelta from BD Pharmingen (clone 14) and resulting blots probed using anti-PKCdelta antisera from Santa Cruz (sc-937). For PKCepsilon, IPs and blots were carried out using monoclonal antibody from BD Pharmingen (clone 21). For PLCgamma2, Syk and Btk IPs, proteins were sequentially immunoprecipitated from each sample, pre-clearing between each IP [25]. Densitometry was analysed using Alpha Imager 220 Documentation and Analysis System Software.
###end p 25
###begin title 26
Pleckstrin phosphorylation
###end title 26
###begin p 27
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Walker1">[29]</xref>
Pleckstrin phosphorylation was monitored as described [29]. The levels of radioactivity in each band were measured using a Phosphorimager SI (Molecular Dynamics) and ImageQuaNT software, version 4.2a.
###end p 27
###begin title 28
Aggregate formation on collagen under shear
###end title 28
###begin p 29
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Calaminus1">[30]</xref>
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Best1">[26]</xref>
Aggregate formation on collagen was carried out as described [30] except that capillaries were imaged using differential interference contrast optics on a Zeiss Axiovert 200M microscope equipped with a Hamamatsu Orca 285 digital camera (Hamamatsu Photonics UK Ltd, Herts, UK). Contents of capillaries were subsequently lysed and levels of adherent platelets assessed by probing for actin [26].
###end p 29
###begin title 30
Statistical analysis of data
###end title 30
###begin p 31
###xml 306 307 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Unless stated otherwise, results are shown as mean+/-SEM. Statistical significance of differences between two means was determined by Student's unpaired T-test or one-way ANOVA. If means were shown to be significantly different, multiple comparisons were performed by the Tukey test. Probability values of P<0.05 were selected to be statistically significant.
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Comparison of novel PKC isoforms in human and mouse platelets
###end title 33
###begin p 34
###xml 231 239 215 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g001">Figure 1</xref>
###xml 494 499 456 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g001">Fig 1</xref>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 213 218 <span type="species:ncbi:9606">human</span>
###xml 314 319 <span type="species:ncbi:9606">human</span>
###xml 425 430 <span type="species:ncbi:10090">mouse</span>
###xml 562 567 <span type="species:ncbi:9606">human</span>
###xml 582 585 <span type="species:ncbi:10116">rat</span>
###xml 671 676 <span type="species:ncbi:10090">mouse</span>
###xml 721 726 <span type="species:ncbi:9606">human</span>
###xml 791 796 <span type="species:ncbi:10090">mouse</span>
###xml 957 962 <span type="species:ncbi:10090">mouse</span>
###xml 967 972 <span type="species:ncbi:9606">human</span>
###xml 1048 1053 <span type="species:ncbi:9606">human</span>
###xml 1089 1094 <span type="species:ncbi:10090">mouse</span>
###xml 1236 1241 <span type="species:ncbi:10090">mouse</span>
###xml 1246 1251 <span type="species:ncbi:9606">human</span>
In human platelets we were able to confirm expression of PKCdelta and theta, but not PKCepsilon and eta even though the antibodies detect expression of these two isoforms in other tissues and cell lines including human HeLa cells (Figure 1 and not shown). We were also unable to detect expression of PKCepsilon in human platelets following attempts to concentrate the protein by immunoprecipitation (not shown). In contrast, mouse platelets express PKCdelta, epsilon and theta, but not PKCeta (Fig 1). Interestingly, we observed robust expression of PKCdelta in human platelets and rat cerebrum using an antibody to rodent PKCdelta but this isoform was hard to detect in mouse platelets. Thus, these results suggest that human platelets robustly express PKCdelta but not PKCepsilon, whereas mouse platelets express higher levels of PKCepsilon and lower levels of PKCdelta. There is precedent for protein isoforms to show species-specific expression between mouse and human platelets, with the PAR1 receptor being the principle thrombin receptor in human platelets, whereas it is absent in mouse platelets. In view of the apparent reciprocal relationship between PKCdelta and PKCepsilon, we focussed our studies on these two isoforms in mouse and human platelets.
###end p 34
###begin title 35
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
Presence of novel PKC isoforms in human and mouse platelets.
###end title 35
###begin p 36
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
Washed human (Hu) or mouse (Mo) platelets were lysed and samples separated by SDS-PAGE. The resulting membranes were blotted with antibodies raised against each isoform. Alongside each sample, the positive control (+) was run, as recommended by the antibody manufacturer. The results are representative of three experiments.
###end p 36
###begin title 37
Investigation of tyrosine phosphorylation of PKCdelta and PKCepsilon
###end title 37
###begin p 38
###xml 588 596 580 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g002">Fig 2A&amp;B</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
There are several reports of robust tyrosine phosphorylation of PKCdelta in human platelets, confirmed in the present study using thrombin and the two GPVI-specific agonists, convulxin and CRP. In human platelets, tyrosine phosphorylation induced by thrombin and convulxin is rapid but transient, returning to near basal levels by 90 sec. Interestingly, in both cases, tyrosine phosphorylation of PKCdelta is sustained in the presence of the general PKC inhibitor, Ro 31-8220, demonstrating that it is under feedback regulation from PKC, although the responsible isoform(s) is not known (Fig 2A&B).
###end p 38
###begin title 39
Effect of Ro 31-8220 (Ro) on PKCdelta tyrosine phosphorylation.
###end title 39
###begin p 40
###xml 299 306 287 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 437 438 425 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human washed platelets in the presence of apyrase (2.5 U/ml) and indomethacin (10 microM) were treated with (A) 1 U/ml thrombin or (B) 3 microg/ml convulxin in the presence or absence of Ro 31-8220 (10 microM, 1 min) for the times shown. Immunoprecipitations and reprobes were carried out as in the methods. Histograms show mean density of bands, normalised according to the basal value. *signifies statistically significant from basal, #signifies statistically significant from equivalent time point without inhibitor. Data is from 3 separate experiments.
###end p 40
###begin p 41
###xml 186 192 178 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g003">Fig 3A</xref>
###xml 194 198 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Crosby1">[11]</xref>
###xml 200 204 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Murugappan1">[13]</xref>
###xml 477 483 469 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g003">Fig 3B</xref>
###xml 600 605 <span type="species:ncbi:9606">human</span>
To address the functional significance of tyrosine phosphorylation of PKCdelta in platelets, we used the Src family kinase inhibitor PP2 to inhibit tyrosine phosphorylation of PKCdelta (Fig 3A) [11], [13]. PP2 had no significant effect on phosphorylation of the major PKC substrate in platelets, pleckstrin, by a sub-maximal (0.1 unit/ml) or maximal (1 unit/ml) concentration of thrombin, although phosphorylation was completely inhibited by the pan-PKC inhibitor, Ro 31-8220 (Fig 3B and not shown). These results demonstrate either that pleckstrin is not significantly phosphorylated by PKCdelta in human platelets or that tyrosine phosphorylation of PKCdelta does not significantly alter its activity.
###end p 41
###begin title 42
(A) Effect of PP2 on PKCdelta tyrosine phosphorylation.
###end title 42
###begin p 43
###xml 199 206 195 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 424 426 420 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1217 1224 1189 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 1530 1537 1492 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 1781 1782 1739 1740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 377 382 <span type="species:ncbi:9606">human</span>
###xml 863 868 <span type="species:ncbi:10090">mouse</span>
###xml 887 892 <span type="species:ncbi:10090">mouse</span>
###xml 1352 1357 <span type="species:ncbi:10090">mouse</span>
###xml 1376 1381 <span type="species:ncbi:10090">mouse</span>
Human washed platelets were treated with 0.1 or 1 U/ml thrombin for 1 min in the presence or absence of PP2 (10 microM, 5 min). Immunoprecipitations and reprobes were carried out as described in the methods. Histogram shows mean density of bands, normalised according to the basal value. (B) Effect of PP2 on pleckstrin phosphorylation in thrombin-stimulated platelets. Washed human platelets were labelled with radioactive 32P-orthophosphate and stimulated with 1 U/ml thrombin for 1 min. PP2 (10 microM, 5 min) or Ro31-8220 (10 microM, 1 min) were added where indicated. After separation by SDS-PAGE, the resulting gel was analysed using a phosphoimager to obtain radioactivity levels. Histogram shows the level of pleckstrin phosphorylation compared to basal levels. Data from one experiment, representative of two. (C) Tyrosine phosphorylation of PKCdelta in mouse platelets. Washed mouse platelets were stimulated with 3 microg/ml CRP or 1 U/ml thrombin in the absence or presence of Ro31-8220 (10 microM, 1 min) (left), or with 1 U/ml thrombin for the times shown (right) in the presence of apyrase (2.5 U/ml) and indomethacin (10 microM). Immunoprecipitations and reprobes were carried out as described in the methods. Histogram shows mean density of bands, normalised according to the basal value. (D) Tyrosine phosphorylation of PKCepsilon in mouse platelets. Washed mouse platelets were stimulated with 3 microg/ml CRP or 1 U/ml thrombin for 1 min. Immunoprecipitations and reprobes were carried out as described in the methods. All studies described in this figure were performed in the presence of apyrase (2.5 U/ml) and indomethacin (10 microM). Histograms show mean density of bands, normalised according to the basal value: *signifies values significant from basal, #signifies significant from equivalent time point without inhibitor. Data is from 3 separate experiments.
###end p 43
###begin p 44
###xml 346 352 342 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g003">Fig 3C</xref>
###xml 626 632 612 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g003">Fig 3D</xref>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
###xml 469 474 <span type="species:ncbi:9606">human</span>
###xml 550 555 <span type="species:ncbi:10090">mouse</span>
In contrast, in mouse platelets thrombin stimulated a rapid, but sustained increase in tyrosine phosphorylation of PKCdelta that was unaltered in the presence of Ro 31-8220, whereas the GPVI-specific agonist CRP had no significant effect on tyrosine phosphorylation of the novel isoform either on its own or in the presence of the PKC inhibitor (Fig 3C). These results demonstrate that regulation of PKCdelta phosphorylation in mouse platelets is distinct from that in human platelets. Some constitutive phosphorylation of PKCepsilon was observed in mouse platelets, which was not altered upon stimulation by CRP or thrombin (Fig 3D), consistent with neither agonist regulating PKCepsilon through tyrosine phosphorylation.
###end p 44
###begin title 45
###xml 32 35 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Functional studies on PKCepsilon-/- mouse platelets
###end title 45
###begin p 46
###xml 387 391 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Castrillo1">[21]</xref>
###xml 612 617 590 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g004">Fig 4</xref>
###xml 758 762 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Castrillo1">[21]</xref>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
###xml 208 213 <span type="species:ncbi:10090">mouse</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 753 757 <span type="species:ncbi:10090">mice</span>
As mouse platelets lacking PKCdelta show increased aggregation in response to collagen, we investigated responses in platelets lacking PKCepsilon. There was no significant difference in the number or size of mouse platelets in PKCepsilon-null mice relative to controls (not shown), consistent with the report of no change in the profile of blood cells in the absence of this PKC isoform [21]. As expected, we could detect no expression of PKCepsilon in platelets purifed from the null mice, and could find no evidence for compensatory changes in expression levels of other isoforms in platelets by western blot (Fig 4). This is consistent with previous reports of no alterations in expression of other isoforms in brain tissue from PKCepsilon-deficient mice [21].
###end p 46
###begin title 47
Expression of PKC isoforms in PKCepsilon-null platelets.
###end title 47
###begin p 48
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Platelets were prepared from PKCepsilon-deficient mice (PKCepsilon-/-) and wild-type littermate controls (WT) and equal protein amounts of whole cell lysates analysed by western blot, using antisera specific for individual PKC isoforms, PKC epsilon, alpha, delta and theta, as indicated.
###end p 48
###begin p 49
###xml 455 461 439 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g005">Fig 5A</xref>
###xml 981 985 959 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Dorsam1">[31]</xref>
Aggregation and dense granule secretion were investigated in PKCepsilon-null platelets using light-scattering aggregometry and luciferin-luciferase luminescence, respectively. The PKCepsilon-null platelets showed a minor delay in the onset of aggregation and a minor reduction in dense granule secretion to concentrations of thrombin (0.03 units/ml) and PAR4 peptide (100 microM) that induces near maximal aggregation in litter-matched control platelets (Fig 5A and not shown). The impairment in response was associated with a slight increase in shape change, which can be explained by the delay in onset of aggregation which has an opposing effect on light transmission. These observations suggest that PKCepsilon makes a minor contribution, alongside other PKC isoforms, to aggregation and secretion mediated through the PAR4 receptor. Consistent with this, there was no significant change in aggregation to ADP (not shown), which induces platelet aggregation independent of PKC [31].
###end p 49
###begin title 50
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Platelet function in PKCepsilon-null mice.
###end title 50
###begin p 51
###xml 89 92 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 440 443 422 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 986 989 950 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1103 1106 1063 1066 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIb</sub>
###xml 1110 1111 1067 1068 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1145 1146 1098 1099 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1150 1151 1100 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
(A) Aggregation and ATP secretion. Washed platelets from PKCepsilon-deficient (PKCepsilon-/-) mice or wild-type (WT) littermate controls were stimulated with the indicated concentrations of CRP, collagen or PAR4 peptide. Aggregation and dense granule secretion were investigated using light-scattering aggregometry and luciferin-luciferase luminescence, respectively. Traces are representative of between 3-7 mice. (B) Spreading. PKCepsilon-/-and wild-type (WT) washed platelets in the presence of apyrase (2.5 U/ml) and indomethacin (10 microM) were exposed to surfaces of 100 microg/ml fibrinogen (FG), 1 U/ml thrombin (Thr), or 100 microg/ml collagen (COLL) for 45 min before fixing and mounting. Representative images from each condition are shown. Histograms depict levels of platelet adhesion to each surface and platelet mean surface area (spreading). The results are from one experiment that is representative of three. (C) Expression levels of surface glycoproteins. PKCepsilon-/- and WT washed platelets were incubated with FITC-labelled antisera against (upper panels) GPVI and integrin alphaIIbbeta3 and (lower panels) integrin alpha2beta1 and expression levels analysed by flow cytometry. The shaded area represents the signal from non-specific IgG control.
###end p 51
###begin p 52
###xml 188 194 188 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g005">Fig 5A</xref>
###xml 308 314 308 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g005">Fig 5A</xref>
###xml 451 457 445 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g005">Fig 5B</xref>
###xml 646 652 620 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g005">Fig 5C</xref>
In contrast, there was a more marked reduction in the onset of aggregation and level of ATP secretion to low and intermediate concentrations of collagen and the GPVI-specific ligand, CRP (Fig 5A). A full recovery in aggregation, although not secretion, was seen at higher concentrations of CRP and collagen (Fig 5A and not shown). However, there was no defect in spreading of PKCepsilon-null platelets on collagen, immobilised fibrinogen or thrombin (Fig 5B). The levels of the two collagen receptors, GPVI and alpha2beta1, and the major platelet integrin, alphaIIbbeta3, were similar in the PKCepsilon-null and litter-matched control platelets (Fig 5C). These results demonstrate a selective impairment in platelet activation through the GPVI collagen receptor which is not the result of an alteration in receptor expression.
###end p 52
###begin title 53
###xml 37 40 31 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Protein phosphorylation in PKCepsilon-/- mouse platelets
###end title 53
###begin p 54
###xml 280 286 274 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g006">Fig 6A</xref>
###xml 483 489 477 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g006">Fig 6B</xref>
###xml 936 942 918 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g006">Fig 6C</xref>
###xml 1386 1392 1354 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g006">Fig 6D</xref>
###xml 1369 1374 <span type="species:ncbi:10090">mouse</span>
###xml 1450 1455 <span type="species:ncbi:9606">human</span>
The molecular basis of the reduced response was investigated by measurement of pleckstrin phosphorylation, revealing a marked reduction downstream of CRP whereas there was only a small decrease in response to thrombin in PKCepsilon-null platelets compared to littermate controls (Fig 6A). This reduction in response to GPVI was associated with a marked decrease in tyrosine phosphorylation induced by the agonist, illustrated by measurement of phosphorylation in whole cell lysates (Fig 6B). The FcRgamma-chain runs as a distinct band in the whole cell lysate and, importantly, its phosphorylation can be seen to be reduced revealing that inhibition occurs at a proximal stage in the signalling cascade. Consistent with this, immunoprecipitation studies reveal reduced tyrosine phosphorylation of several other signalling proteins that lie downstream of the FcRgamma-chain in the GPVI signalling cascade, namely Syk, Btk and PLCgamma2 (Fig 6C). These results therefore identify a role for PKCepsilon in the GPVI signalling pathway that is mediated by a reduction in phosphorylation of the FcRgamma-chain underlying the selective defect in response to collagen and CRP. Consistent with this, a pan PKC inhibitor, Ro 31-8220, reduces CRP-stimulated tyrosine phosphorylation in whole cell lysates (not shown) and of the FcRgamma-chain and Syk in Syk immunoprecipitates in mouse platelets (Fig 6D), although interestingly a similar effect is not seen in human platelets (not shown).
###end p 54
###begin title 55
(A) Pleckstrin phosphorylation in PKCepsilon-null platelets.
###end title 55
###begin p 56
###xml 54 57 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 128 130 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 556 559 530 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 603 606 571 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 743 750 707 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 896 899 844 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1038 1045 982 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 1404 1411 1340 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 1121 1126 <span type="species:ncbi:10090">mouse</span>
Washed platelets from PKCepsilon-deficient (PKCepsilon-/-) mice or wild-type (WT) littermate controls labelled with radioactive 32P-orthophosphate were stimulated in the presence of apyrase (2.5 U/ml) and indomethacin (10 microM) with 0.1 U/ml thrombin or 0.3 microg/ml CRP for 1 min. After separation by SDS-PAGE the resulting gel was analysed using a phospho-imager to obtain radioactivity levels. The level of pleckstrin phosphorylation is shown in a histogram with values normalised to basal levels. B) Whole cell tyrosine phosphorylation in PKCepsilon-/- platelets. Washed platelets from PKCepsilon-/- or WT littermate controls were stimulated for 60 sec with 1 or 3 microg/ml CRP before lysis. SDS-PAGE gels were run as described in the methods. The arrow shows position of the FcR gamma-chain. (C) Tyrosine phosphorylation downstream of GPVI in PKCepsilon-null platelets. Washed PKCepsilon-/- or WT platelets were stimulated for 60 sec with 0.3 microg/ml CRP. Immunoprecipitations and reprobes were carried out as described in the methods. (D) The effect of Ro31-8220 on tyrosine phosphorylation in CRP-stimulated mouse platelets. Washed WT platelets were pre-incubated with (Ro) or without (-) Ro 31-8220 (10 microM, 1 min) prior to harvesting without (B) or with stimulation for 60 sec with 1 microg/ml CRP. Syk was immunoprecipitated and western blotted for phosphotyrosine as described in the methods. The location of Syk and the coprecipitated FcR gamma-chain are shown. For all the above, results are representative of between 2-5 experiments.
###end p 56
###begin title 57
###xml 57 60 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
Platelet aggregation under arteriolar shear in PKCepsilon-/- mouse platelets
###end title 57
###begin p 58
###xml 174 177 168 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 354 360 348 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g007">Fig 7A</xref>
###xml 447 453 441 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003793-g007">Fig 7B</xref>
###xml 873 877 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Best1">[26]</xref>
###xml 1052 1053 1036 1037 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
The consequence of the defect in GPVI receptor signalling on aggregate formation on a collagen surface at arteriolar shear was investigated. Blood from control and PKCepsilon-/- mice rapidly forms platelet aggregates on collagen, which continue to increase in size over the course of several minutes, with no discernable difference in either population (Fig 7A). Consistent with this, there was no significant difference in surface area coverage (Fig 7B) or the level of platelet protein as measured by western blotting for actin (not shown). The lack of an effect on platelet aggregation under arteriolar flow in the absence of PKCepsilon is consistent with previous reports of unaltered aggregate formation on collagen under similar conditions in mice that have a reduced level of the GPVI-FcRgamma-chain complex, despite the partial reduction in aggregation to collagen [26]. This is presumably because the inhibition of the response to collagen is partial and aggregate growth under arteriolar shear is driven by the secondary mediators ADP and TxA2.
###end p 58
###begin title 59
###xml 55 58 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Platelet adhesion to collagen under flow in PKCepsilon -/- mice.
###end title 59
###begin p 60
###xml 21 24 15 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 128 130 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 339 346 333 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Blood from PKCepsilon-/- mice or wild-type (WT) littermate controls was flowed over collagen for 4 min at a shear rate of 1000 s-1, then rinsed with Tyrode's buffer for 5 min. A. Adherent platelets and aggregates were imaged by DIC microscope and representative images are shown. B. The surface coverage was calculated as described in the methods and is shown as the mean+/-s.e.m. from four experiments.
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 629 633 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Pula1">[20]</xref>
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
###xml 723 728 <span type="species:ncbi:10090">mouse</span>
###xml 798 803 <span type="species:ncbi:10090">mouse</span>
###xml 947 952 <span type="species:ncbi:10090">mouse</span>
The present study demonstrates a selective role for PKCepsilon in GPVI signalling in mouse platelets with impaired aggregation and secretion to collagen and CRP. In comparison, aggregation and secretion induced through the PAR4 receptor are only marginally inhibited, consistent with a minor role for this PKC isoform in supporting activation alongside other PKC isoforms. The selective defect in GPVI signalling in PKCepsilon-deficient platelets contrasts sharply with that of PKCdelta, as platelets from mice deficient in the latter show increased filopodia formation on CRP and increased aggregation to collagen in suspension [20]. This demonstrates unique functions for the two novel PKC isoforms downstream of GPVI in mouse platelets. The defect in GPVI signalling seen in the PKCepsilon-null mouse platelets is not due to a change in the level of expression of GPVI or alpha2beta1. The observation that aggregation to ADP was not altered in mouse platelets argues against a role for a change in expression of integrin alphaIIbbeta3, a result confirmed by flow cytometry.
###end p 62
###begin p 63
###xml 518 522 504 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Germano1">[32]</xref>
###xml 724 728 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Swann1">[33]</xref>
###xml 1446 1454 1402 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1454 1458 1410 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Germano1">[32]</xref>
###xml 1249 1254 <span type="species:ncbi:9606">human</span>
###xml 1289 1294 <span type="species:ncbi:10090">mouse</span>
###xml 1331 1336 <span type="species:ncbi:10090">mouse</span>
###xml 1594 1599 <span type="species:ncbi:10090">mouse</span>
###xml 1776 1781 <span type="species:ncbi:9606">human</span>
###xml 1947 1952 <span type="species:ncbi:10090">mouse</span>
###xml 1957 1962 <span type="species:ncbi:9606">human</span>
The reduction in response to GPVI can be accounted for by a decrease in tyrosine phosphorylation at a proximal stage of its signalling cascade, as phosphorylation of the FcRgamma-chain and Syk are reduced. A mechanism to explain this has been described in mast cells, where, in response to activation of the FcepsilonRI receptor, PKC phosphorylates the FcRgamma-chain on threonine-60, two residues downstream of the conserved C-terminal tyrosine residue which is phosphorylated in the ITAM, leading to Syk association [32]. Expression of a mutated form of the FcRgamma-chain with threonine-60 replaced by alanine led to reduced association and activation of Syk and subsequent inhibition of degranulation in response to IgE [33]. The authors speculate that phosphorylation of the ITAM by a novel PKC isoform increases binding of Syk to the ITAM and enhances activation, illustrated by the increase in tyrosine phosphorylation of Syk and downstream proteins. We speculate that this increase in binding of Syk to the FcRgamma-chain protects the ITAM moiety from dephosphorylation leading to a net increase in tyrosine phosphorylation. In mast cells, PKCdelta is responsible for the phosphorylation. However, although PKCdelta is expressed robustly in human platelets, it is at low levels in mouse platelets. PKCepsilon is present in mouse platelets and, as for PKCdelta, its recombinant form does mediate phosphorylation of the FcRgamma-chain ITAM in vitro[32]. Tyrosine phosphorylation of the FcRgamma-chain, Syk and downstream proteins is also reduced in the presence of a pan-PKC inhibitor in mouse platelets, confirming that the reduction in tyrosine phosphorylation of FcRgamma-chain is mediated by the loss of a PKC isoform. Interestingly, a similar result is not seen in human platelets, which, although consistent with the low levels of PKCepsilon, is surprising given the presence of PKCdelta. This may reflect a further difference between mouse and human platelets in the role of novel PKC isoforms.
###end p 63
###begin p 64
###xml 159 165 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 343 347 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Crosby1">[11]</xref>
###xml 349 353 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Crosby2">[14]</xref>
###xml 355 359 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Buensuceso1">[16]</xref>
###xml 361 365 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Murugappan2">[17]</xref>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 221 226 <span type="species:ncbi:9606">human</span>
###xml 654 659 <span type="species:ncbi:9606">human</span>
Our inability to detect expression of PKCepsilon in human platelets was not expected as there are several reports describing its presence. However, Buensuceso et al. were also unable to detect expression of PKCepsilon in human platelets although both positive and negative studies used the same source of antibodies as used in the present one [11], [14], [16], [17]. Our attempt to address this through concentration of PKCepsilon by immunoprecipitation was unsuccessful. Whilst the explanation for this discrepancy is not known, and may reflect differences in batches of antibodies, the cumulative reports illustrate that PKCepsilon is either absent in human platelets or present at a very low level.
###end p 64
###begin p 65
###xml 464 468 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Jones1">[34]</xref>
###xml 529 537 521 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 547 554 539 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 949 953 933 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Murugappan1">[13]</xref>
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 438 443 <span type="species:ncbi:9606">human</span>
###xml 697 702 <span type="species:ncbi:10090">mouse</span>
###xml 933 938 <span type="species:ncbi:9606">human</span>
###xml 1013 1018 <span type="species:ncbi:10090">mouse</span>
###xml 1129 1134 <span type="species:ncbi:9606">human</span>
###xml 1139 1144 <span type="species:ncbi:10090">mouse</span>
The present study demonstrates that the tyrosine phosphorylation of PKCdelta seen in human platelets is down-regulated through a PKC-dependent pathway. The molecular basis of this is not known, although it could be dependent upon the direct or indirect regulation of a protein tyrosine phosphatase. For example the SHP-1 tyrosine phosphatase interacts with PKCalpha and is phosphorylated on a consensus PKC phosphorylation site following human platelet activation [34]. Phosphorylation of SHP-1 negatively regulates its activity in vitro, but the in vivo consequences of phosphorylation may be more complex, with the potential to regulate substrate specificity and localisation. Interestingly, in mouse platelets tyrosine phosphorylation of PKCdelta is sustained, further emphasising the species-specific functions and regulation of PKC isoforms. PAR4 has been reported to stimulate sustained tyrosine phosphorylation of PKCdelta in human platelets [13], and this is the major signalling receptor for thrombin in mouse platelets. Thus, the difference in kinetics may reflect differential expression and roles of PAR1 and PAR4 in human and mouse platelets.
###end p 65
###begin p 66
###xml 262 266 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Hall1">[12]</xref>
###xml 753 757 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003793-Briddon1">[35]</xref>
###xml 201 206 <span type="species:ncbi:9606">human</span>
Although frequently used as a marker of PKCdelta activation, the functional significance of its tyrosine phosphorylation is unclear. It has been reported to increase the kinase activity of PKCdelta in human platelets but is not required for membrane association [12]. This study shows that blockade of Src kinases, and hence phosphorylation of PKCdelta, does not alter pleckstrin phosphorylation in thrombin-stimulated platelets, arguing against direct regulation of enzymatic activity, with the caveat that PKCdelta may not play a major role in regulating pleckstrin phosphorylation. The lack of Src kinase blockade on pleckstrin phosphorylation is consistent with the fact that Src kinases play a minimal role in thrombin-induced platelet aggregation [35], again questioning the significance of PKCdelta tyrosine phosphoryation in this signalling pathway. The significance of tyrosine phosphorylation of PKCdelta downstream of GPVI remains to be established.
###end p 66
###begin p 67
###xml 415 420 <span type="species:ncbi:10090">mouse</span>
###xml 425 430 <span type="species:ncbi:9606">human</span>
In conclusion, the present study has provided further evidence for specific regulation and functions of PKC isoforms by focussing on the two novel PKCs, PKCdelta and PKCepsilon, and in particular has shown that PKCepsilon plays a critical role in potentiating the proximal events in the GPVI signalling pathway. Further, it has also demonstrated differences in expression and phosphorylation of the two isoforms in mouse and human platelets further revealing species-specific functions of individual isoforms.
###end p 67
###begin p 68
We would like to thank Peter Parker for generously providing reagents.
###end p 68
###begin title 69
References
###end title 69
###begin article-title 70
GPVI and integrin alphaIIb beta3 signaling in platelets.
###end article-title 70
###begin article-title 71
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.
###end article-title 71
###begin article-title 72
Phosphorylation-dependent and -independent pathways of platelet aggregation.
###end article-title 72
###begin article-title 73
Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin.
###end article-title 73
###begin article-title 74
Activation of protein kinase C is required for the stable attachment of adherent platelets to collagen but is not needed for the initial rapid adhesion under flow conditions.
###end article-title 74
###begin article-title 75
###xml 154 159 <span type="species:ncbi:9606">human</span>
Vasodilator-stimulated phosphoprotein (VASP) is phosphorylated on Ser157 by protein kinase C-dependent and -independent mechanisms in thrombin-stimulated human platelets.
###end article-title 75
###begin article-title 76
Exposure of ligand-binding sites on platelet integrin alpha IIB/beta 3 by phosphorylation of the beta 3 subunit.
###end article-title 76
###begin article-title 77
Protein kinase C regulates pleckstrin by phosphorylation of sites adjacent to the N-terminal pleckstrin homology domain.
###end article-title 77
###begin article-title 78
The extended protein kinase C superfamily.
###end article-title 78
###begin article-title 79
Protein kinase C-delta activation and tyrosine phosphorylation in platelets.
###end article-title 79
###begin article-title 80
###xml 94 99 <span type="species:ncbi:9606">human</span>
Physical and functional interaction between protein kinase C delta and Fyn tyrosine kinase in human platelets.
###end article-title 80
###begin article-title 81
###xml 37 42 <span type="species:ncbi:9606">human</span>
Coincident regulation of PKCdelta in human platelets by phosphorylation of Tyr311 and Tyr565 and phospholipase C signalling.
###end article-title 81
###begin article-title 82
Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets.
###end article-title 82
###begin article-title 83
Interaction of Bruton's tyrosine kinase and protein kinase Ctheta in platelets. Cross-talk between tyrosine and serine/threonine kinases.
###end article-title 83
###begin article-title 84
A role for PKCtheta in outside-in alpha(IIb)beta3 signaling.
###end article-title 84
###begin article-title 85
Regulation of outside-in signaling in platelets by integrin-associated protein kinase C beta.
###end article-title 85
###begin article-title 86
###xml 98 103 <span type="species:ncbi:9606">human</span>
Differential role of protein kinase C delta isoform in agonist-induced dense granule secretion in human platelets.
###end article-title 86
###begin article-title 87
Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta.
###end article-title 87
###begin article-title 88
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
###end article-title 88
###begin article-title 89
PKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation.
###end article-title 89
###begin article-title 90
Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection.
###end article-title 90
###begin article-title 91
Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens.
###end article-title 91
###begin article-title 92
Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes.
###end article-title 92
###begin article-title 93
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen.
###end article-title 93
###begin article-title 94
c-Cbl negatively regulates platelet activation by glycoprotein VI.
###end article-title 94
###begin article-title 95
GPVI levels in platelets: relationship to platelet function at high shear.
###end article-title 95
###begin article-title 96
Distinct but critical roles for integrin alphaIIbbeta3 in platelet lamellipodia formation on fibrinogen, collagen-related peptide and thrombin.
###end article-title 96
###begin article-title 97
Glycoprotein IIb-IIIa-dependent aggregation by glycoprotein Ibalpha is reinforced by a Src family kinase inhibitor (PP1)-sensitive signalling pathway.
###end article-title 97
###begin article-title 98
###xml 105 110 <span type="species:ncbi:9606">human</span>
Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets.
###end article-title 98
###begin article-title 99
A major role for Scar/WAVE-1 downstream of GPVI in platelets.
###end article-title 99
###begin article-title 100
###xml 100 105 <span type="species:ncbi:9606">human</span>
Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets.
###end article-title 100
###begin article-title 101
Phosphorylation of the gamma chain of the high affinity receptor for immunoglobulin E by receptor-associated protein kinase C-delta.
###end article-title 101
###begin article-title 102
Requirement for a negative charge at threonine 60 of the FcRgamma for complete activation of Syk.
###end article-title 102
###begin article-title 103
###xml 44 49 <span type="species:ncbi:9606">human</span>
Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus.
###end article-title 103
###begin article-title 104
###xml 88 93 <span type="species:ncbi:9606">human</span>
Evidence for the involvement of p59fyn and p53/56lyn in collagen receptor signalling in human platelets.
###end article-title 104
###begin p 105
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 105
###begin p 106
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was funded by the British Heart Foundation and The Wellcome Trust. KT was funded by a British Heart Foundation Studentship. SPW holds a BHF Chair. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 106

